Home
|Insights
|Apotex Challenges Amgen Cancer Biologic Patent As Obvious

PDF Link

Apotex Challenges Amgen Cancer Biologic Patent As Obvious

Press Coverage | 12.13.17

Attachments

Download Attachment
20171213 Apotex Challenges Amgen Cancer Biologic Patent As Obvious

Contacts

Michael H. Jacobs
Partner
- Washington, D.C.
  - D | +1.202.624.2568
bWphY29ic0Bjcm93ZWxsLmNvbQ==
Deborah H. Yellin
Partner
She/Her/Hers
- Washington, D.C.
  - D | +1.202.624.2947
ZHllbGxpbkBjcm93ZWxsLmNvbQ==
Shannon Lentz
Partner
She/Her/Hers
- Washington, D.C.
  - D | +1.202.624.2897
c2xlbnR6QGNyb3dlbGwuY29t

Insights

Press Coverage | July 2025

WorldWatch: Cyber security

Press Coverage | 06.27.25
An Inspirational Duke Professor’s Last Lesson
Press Coverage | 06.26.25
Crowell & Moring’s New Partner Talks Navigating Privacy, AI Laws in the Midst of ‘Technological Revolution’
Press Coverage | 06.24.25
Former DHS Deepfakes Expert Joins Crowell & Moring

View All Insights

Subscribe

to the latest insights from our team